Wedbush maintains Outperform rating on Xencor, $45 price target

What happened

Wedbush maintained an Outperform rating on Xencor's stock with a $45.00 price target, which implies 54.2% upside from the October 26 close of $29.18. The note cited a 45% confirmed overall response rate for XmAb819 in heavily pretreated patients with clear cell renal cell carcinoma.

Confirmed

Global impact / market context

An Outperform rating means the analyst expects the stock to beat the market, and the $45.00 target suggests significant upside. The 45% response rate supports Xencor's case for accelerated approval, which means a faster regulatory path, potentially bringing XmAb819 to patients and revenue sooner.

Analyst inference

Xencor is developing XmAb819 for clear cell renal cell carcinoma, which means kidney cancer with high unmet need. Wedbush's two-track plan, a global randomized study plus FDA discussions for accelerated approval, could let Xencor capture market share if the data holds up.

Analyst inference

What to watch

1. Wedbush's $45.00 price target and Outperform rating imply the analyst sees 54.2% upside from the October 26 close of $29.18, so the stock's actual path toward that level is a key measure. Confirmed
2. Xencor plans a global randomized study of XmAb819 and discussions with the FDA for accelerated approval, which means a faster review pathway; watch whether these steps are formally announced and completed. Proposed
3. Watch the durability of the 45% confirmed overall response rate in heavily pretreated ccRCC patients, since sustained efficacy data would strengthen the accelerated approval case and support the commercial outlook. Analyst inference

Evidence

• Original source link unavailable